Longevity gets real, GLP-1 gets specific, and screening misses big.

Today's reads show longevity pushing into clinical practice, GLP-1s diversifying beyond weight loss, and systemic screening failures creating health disparities.

In today's read: 1. The longevity industry matures into medical delivery. · 2. GLP-1s diversify beyond weight loss, signaling precision medicine. · 3. Policy and screening protocols are failing vulnerable populations. · 4. Nervous system regulation is the root of complex health issues.

1. The longevity industry matures into medical delivery.

Longevity is moving past supplements and biohacking. It's now establishing physical clinics and developing drug pipelines aimed at age-related disease. This shifts the unit economics from direct-to-consumer sales to a more traditional, clinic-based reimbursement model and FDA pathways.

Watch for more specialized longevity clinics, like Morrow's new facility in Singapore, and biotech firms, like Niagen Bioscience, moving into human trials for NAD+ drugs. This signals a shift toward medicalizing longevity, attracting more traditional healthcare investment but also raising questions about access and cost.

Evidence from today:

• Morrow opens 45,000 sq ft longevity clinic in Singapore — Longevity.Technology — Morrow launched its flagship longevity clinic in Singapore, a massive 45,000 sq ft space focused on preventive healthcare. It combines clinical medicine with lifestyle interventions, positioning itself for international expansion. The aim is to make continuous preventive care more accessible to a high-net-worth client base.
• Niagen Bioscience preps NAD+ drug for rare disease human trials — Longevity Technology — Niagen Bioscience and partner NAD Pharmaceuticals tapped Evotec to run preclinical studies for NB4168, a new drug designed to boost NAD+ levels. The work, including pharmacokinetics and pharmacodynamics, will happen in Evotec's Verona, Italy lab. This moves the drug closer to human trials for rare diseases.
• Aging clocks are tools, not a final verdict — Longevity Technology — Steve Horvath, the guy behind the original epigenetic clock, spoke ahead of the Longevity Investors Conference. He's saying these biological age tests are for tracking progress, not for telling you how long you have left. Think of them as a compass, not a crystal ball.

2. GLP-1s diversify beyond weight loss, signaling precision medicine.

GLP-1 receptor agonists are expanding their therapeutic targets. While semaglutide and tirzepatide show varying cardiovascular benefits, new drugs like pemvidutide are entering Phase 3 for fatty liver disease, and intra-articular GLP-1s for knee pain are in trials. This indicates a move towards precision medicine where specific GLP-1 formulations are tailored for different conditions and mechanisms of action beyond appetite suppression.

Don't think of GLP-1s as just weight loss drugs. Expect to see new indications and formulations emerge for conditions like osteoarthritis and MASH, pushing pharmaceutical companies to differentiate their products based on broader health benefits, not just pounds lost. This signals a future where GLP-1s become a class of drugs with diverse applications.

Evidence from today:

• 4Moving Biotech finishes Phase 2a trial for GLP-1 knee pain jab — Longevity Technology — 4Moving Biotech just wrapped up enrollment for its Phase 2a trial of 4P004, an intra-articular GLP-1 receptor agonist for knee osteoarthritis. This randomized, double-blind, placebo-controlled study included 129 patients across Europe and the US. The drug aims to target inflammatory mechanisms behind pain and disease progression.
• Study Ranks GLP-1s for Cardiovascular Health — Mindbodygreen — A new study published in the New England Journal of Medicine found that specific GLP-1 medications, notably semaglutide (Ozempic/Wegovy) and tirzepatide (Zepbound/Mounjaro), showed better cardiovascular outcomes compared to dulaglutide (Trulicity). This suggests that not all GLP-1s are created equal for heart health, pushing patients and doctors to consider specific drug profiles beyond just weight loss.
• Altimmune starts Phase 3 trial for fatty liver drug pemvidutide — Longevity Technology — Altimmune began enrolling patients in a Phase 3 trial for pemvidutide, its dual-agonist drug for metabolic dysfunction-associated steatohepatitis (MASH), aka fatty liver disease. The drug works on both glucagon and GLP-1 receptors. It's also being studied for alcohol use disorder, which is interesting.

3. Policy and screening protocols are failing vulnerable populations.

Existing healthcare policies and screening methods are missing significant numbers of at-risk individuals, leading to preventable harm. This is seen in low Medicare genomic testing rates for cancer, inadequate breast cancer screening for younger women, and rising Vitamin K deficiency in newborns due to parental refusal of prophylaxis. It exposes systemic gaps in access, education, and effective intervention.

These failures point to a growing disparity in health outcomes driven by policy-level missteps and information gaps. Watch for increased pressure on health systems to update screening criteria and improve patient education, or face escalating costs and worsened public health metrics. This indicates a continued struggle to translate medical knowledge into equitable care delivery.

Evidence from today:

• Medicare cancer genomic testing still under 20% — Inside Precision Medicine — Genomic testing, critical for guiding cancer treatment, is still only used by less than 20% of Medicare beneficiaries. This is despite broader coverage since 2018, meaning many patients aren't getting the personalized care that could improve outcomes.
• UK Breast Cancer Criteria Miss 95% of Cases Under 50 — Inside Precision Medicine — UK researchers found current breast cancer referral criteria miss over 95% of women under 50 who develop breast cancer within a decade. A multifactorial model identified eight times more cases, suggesting existing screening protocols are severely underperforming for younger populations.
• Vitamin K shots prevent brain bleeds in newborns, Swedish study finds — Deutsches Ärzteblatt — A nationwide Swedish cohort study in JAMA Pediatrics linked rising Vitamin K deficiency bleeding (VKDB) in newborns, including brain hemorrhages, to parents refusing prophylactic Vitamin K shots. This trend follows an increase in parents opting out of intramuscular Vitamin K for their infants. The findings reinforce the critical role of Vitamin K in infant health.

4. Nervous system regulation is the root of complex health issues.

Multiple lines of research show that regulating the nervous system is a common pathway to addressing diverse health challenges. From brain stimulation changing gene expression to THC reducing PTSD nightmares, and the gut microbiome influencing allergies or endometriosis, the body's control center is often the leverage point. This highlights the vagal nerve and neuroimmune axes as central to health and disease.

Look for continued investment in neuro-modulatory therapies and a deeper understanding of the gut-brain axis for conditions far beyond traditional mental health. This suggests that interventions aimed at nervous system regulation, whether through biotech, nutrition, or behavioral change, will become increasingly central to treating chronic and complex diseases, pushing us away from symptom management.

Evidence from today:

• Brain stimulation changes how genes are expressed in human neurons — Nature News — New research published in Nature found that brain stimulation can change gene activity in specific human brain cells. Led by Dr. N. N. Panagiotaropoulos, the study involved 1,215 patients and revealed a direct link between electrical activity and gene expression in neurons. This suggests targeted therapies could eventually re-wire brain function for conditions like depression or epilepsy.
• Stressed amygdala astrocytes activate fear response in mice — Nature News — New research in Nature, led by Dr. Shu-Guang Wang at Xi'an Jiaotong University, found that primary cilia on amygdala astrocytes are key to how mice process fear and stress. When these cilia were blocked, mice showed fewer stress behaviors. It suggests a new pathway for understanding and potentially treating anxiety.
• THC reduces nightmares in PTSD patients in new Charité study — Deutsches Ärzteblatt — A new randomized controlled study from Berlin's Charité, published in Nature Medicine, found the cannabis compound THC helped over half of PTSD patients sleep better by reducing nightmares. This isn't just about sleep quality; it's about re-regulating a nervous system constantly on high alert from trauma. The research suggests THC could be a targeted treatment for a very specific and debilitating symptom.
• Fecal capsules cut peanut allergy in six adults — New Scientist — A small clinical trial found that swallowing fecal matter from a non-allergic donor improved peanut tolerance in six adults with severe peanut allergies. This suggests that altering the gut microbiome could be a new approach to managing allergies. The study, led by Dr. R. G. Hamilton, was published in the New Scientist and points to the gut's critical role in immune response.
• Specific Gut Bacteria Linked to Endometriosis — Inside Precision Medicine — New research published in Inside Precision Medicine has identified a clear link between high levels of the gut bacterium Olsenella profusa and its metabolite lysophosphatidylcholine in stool, and the presence of endometriosis. This finding offers a potential new biomarker for diagnosis and treatment. For anyone with debilitating pelvic pain, this suggests a new avenue for investigation beyond the usual suspects.

Also moved today

• Outside Online calls for more women over 50 in outdoor media — Outside Online — Outside Online is calling for better representation of women over 50 in outdoor media, a signal that consumer demands are shifting toward inclusive aging narratives.
• Screen Time Tied to Brain Changes 20 Years Later — Mindbodygreen — A new JAMA study links high screen time in midlife to brain changes two decades later, but notes that passive viewing (like TV) showed a stronger negative correlation than active use (computers).
• Studies Find Screen Time Not Clearly Harmful for Kids — Deutsches Ärzteblatt — New studies from Scotland and Sweden show no clear negative effects of longer screen times on kids and teens, challenging existing screen time policies.
• Longer anti-platelet therapy after coronary stent improves outcomes — Deutsches Ärzteblatt — Longer anti-platelet therapy after a coronary stent significantly reduces adverse heart events, highlighting the benefit of extended secondary prevention for at-risk individuals.
• German Diabetes Society Calls for CGM Quality Standards — Deutsches Ärzteblatt — The German Diabetes Society is pushing for quality standards in continuous glucose monitoring (CGM) systems, which suggests regulatory bodies are catching up to widespread device adoption.
• Viruses reactivate in acute and long COVID, say Nature researchers — Nature News — Viruses like Epstein-Barr virus reactivate in both acute and long COVID, suggesting persistent viral activity contributes to post-viral symptoms.
• Most people can't spot AI-written personal messages, study finds — Videnskab.dk (Health) — Most people can't tell if a personal message was written by AI or a human, indicating a growing challenge for authentic digital connection and communication.
• Cyclospora Outbreak in US Hits 10,000 Confirmed Cases — Deutsches Ärzteblatt — A Cyclospora outbreak has hit over 10,000 confirmed cases in the US, indicating a significant public health issue linked to contaminated produce and food safety vulnerabilities.
• Topo Athletic launches new carbon-plated racing shoe for speed — Podium Runner / Triathlete Science — Topo Athletic launched its first carbon-plated racing shoe, showing how athletic performance tech continues to trickle down from elite to everyday products.
• Germany plans to merge three food and nutrition agencies — Deutsches Ärzteblatt — Germany plans to merge three food and nutrition agencies to streamline oversight, indicating a national push for more unified public health messaging and food quality control.

New this week in wellness goods

• Topo Athletic launches new carbon-plated racing shoe for speed — global — Topo Athletic just dropped the Specter Elite, its first carbon-plated racing shoe. This move aims to boost speed for runners with a specific foot geometry, adding more spring to your step on race day.
• UltraPod converts old iPhones into music-first dumbphones — global — UltraPod, a new app, lets you repurpose an old iPhone into a music-only device, stripping out most smart features. It aims to reduce screen time and digital distractions, offering a dedicated tool for focused listening without notifications. This gives old tech new life and a way to consciously manage your attention.
• Haut.AI launches software for remote skin research — B2B — Haut.AI released new Clinical Studies Software, a platform for beauty, skincare, and dermatology companies to run remote and hybrid clinical trials. It standardizes image capture and AI measurement for 48 skin biomarkers like wrinkles, pigmentation, and acne. This means companies can test products faster and at a larger scale.

Signal map

North America: 21 · Global: 16 · Europe: 12 · Oceania: 1 · Nordics: 1

What I'd watch next

Keep an eye on the regulatory response to screening failures, especially in cancer detection and infant health, as public pressure mounts. Also, watch for new GLP-1 indications; the market is expanding fast beyond initial weight loss applications. Expect more discussion around nervous system regulation and its centrality to almost every health outcome.

Where this fits at Kokorology

These threads make a strong case for building resilience where it actually counts: in your nervous system. That's why we built the Nervous System Journal for exactly this kind of regulatory work.